#Shionogi

Completed the transfer of rights for the Edaravone business from Tanabe Pharma effective April 1, 2026, and established the Radicava business company. Annual sales revenue of approximately 700 million USD expected from fiscal year 2026.

Shionogi invested 2,125 million USD to acquire 21.7% of shares in ViiV Healthcare Ltd., completing the equity-method affiliate status.

Shionogi & Co., Ltd. has concluded a 300 billion yen bridge loan agreement on March 27, 2026, related to an additional investment in ViiV Healthcare Ltd., with borrowing execution planned for March 31.

Shionogi & Co., Ltd. has resolved to acquire a 50% stake in Shionogi-Apnimed Sleep Science, LLC held by Apnimed for 100 million USD (approx. 15.952 billion JPY), making it a consolidated subsidiary.

Shionogi & Co., Ltd.'s anti-SARS-CoV-2 drug Xocova® obtained additional approval in Japan for post-exposure prevention of COVID-19. Impact on FY ending March 2026 earnings is minimal.

Shionogi & Co., Ltd. has applied for manufacturing and marketing approval of the 0.5% lotion formulation of the atopic dermatitis treatment "Collectim®." Safety and bioequivalence were confirmed through Phase 1 skin safety and Phase 3 bioequivalence studies.

Shionogi & Co., Ltd. has decided on the basic policy to absorb its wholly owned subsidiary Torii Pharmaceutical Co., Ltd. through a merger effective April 1, 2027.

In the third quarter of the fiscal year ending March 2026, Shionogi & Co., Ltd. achieved revenue of 360.7 billion yen (8.1% YoY increase), operating income of 148.7 billion yen (15.1% YoY increase), and quarterly profit of 158.2 billion yen (18.7% YoY increase), realizing growth in both revenue and profit.

For the third quarter of the fiscal year ending March 2026, revenue was 360,684 million yen (8.1% YoY increase), operating income was 148,739 million yen (15.1% YoY increase), and net income attributable to owners of parent for the quarter was 158,225 million yen (18.3% YoY increase). The consolidation of Torii Pharmaceutical as a subsidiary and the absorption-type split of JT’s...

Shionogi & Co., Ltd. plans to invest USD 2.125 billion (approximately JPY 334.793 billion) to increase its voting rights ratio in ViiV Healthcare Ltd. from 10.0% to 21.7%, thereby achieving application as an equity-method affiliate (to be acquired by the end of March 2026).

Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug "Zazvey® Capsules 30mg" in Japan and has launched it in the market as a novel mechanism of action treatment with rapid onset.

Shionogi & Co., Ltd. has obtained domestic manufacturing and marketing approval for the depression treatment drug 'Zavege® Capsules 30mg' in Japan and has started market launch as a novel mechanism of action treatment with rapid efficacy.